Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 7, 2026Canadian Journal of Respiratory Critical Care and Sleep MedicineOpen Access

Obstructive sleep apnea pharmacology

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBernie Y. SunwooCSChristopher N. SchmicklAMAtul Malhotra

Discussion

Loading...

Member takes

Overview

Review explores pharmacotherapies improving treatment adherence and OSA outcomes in patients.

Key Points

  • The review aims to summarize the pharmacological treatments available for obstructive sleep apnea (OSA) and their effectiveness.
  • Overview of pharmacotherapeutic approaches to improve CPAP adherence
  • Discussion of anti-obesity medications like tirzepatide for OSA patients with obesity
  • Examination of the potential for endotype-targeted therapies in clinical practice.
  • Tirzepatide improves OSA severity in individuals with obesity and is FDA-approved for moderate-to-severe cases.
  • Pharmacotherapies show promise in enhancing nasal patency and facilitating sleep initiation for CPAP users.
  • Need for further research on translating endotype-targeted treatments into clinical settings remains.

Cite This Study

Sunwoo et al. (2026) studied this question.

synapsesocial.com/papers/6a758b54847ab6d26c01ec15https://doi.org/10.1080/24745332.2026.2695024
View Full Paper
Ask AI
Bookmark
Share